Lilly Has Early Access Rights To BioAge’s ‘Exercise In A Pill’ Data

The big pharma will get a first peak at BioAge’s Phase II results for azelaprag, but the biotech is keeping its options open with an ‘incretin-agnostic’ strategy for its exerkine candidate.